Latest News

Johnson & Johnson Tops Profit Estimates but Trims Full-Year Outlook

18237500 - businessman hand pointing to investment as concept
Text size

Mark Ralston/AFP via Getty Images

Johnson & Johnson

reported second-quarter adjusted earnings of $2.59 a share, topping analysts’ estimates, but the healthcare giant trimmed its fiscal-year adjusted earnings outlook.

Johnson & Johnson

(ticker: JNJ) shares were up 0.7% in premarket trading Tuesday to $175.42.

Sales in the quarter rose 3% to $24 billion. Pharmaceutical sales rose 6.7% to $13.3 billion. Revenue from Covid-19 vaccines of $544 million beat Wall Street estimates.

Analysts surveyed by FactSet expected the company to earn $2.54 a share on revenue of $23.8 billion. A year earlier, Johnson & Johnson earned $2.48 a share on revenue of $23.3 billion.

The world’s largest healthcare company said Tuesday it expected adjusted earnings for the full year of $10 to $10.10 a share, down from previous guidance of $10.15 to $10.35 a share. Sales for the year were forecast at $93.3 billion to $94.3 billion vs. previous expectations of $94.8 billion to $95.8 billion.

The company cited a stronger dollar for the adjustment to its 2022 outlook.

Johnson & Johnson was one of Barron’s stock picks for 2022. Since the beginning of the year, JNJ shares have risen almost 1.9%. The

S&P 500
has dropped 19.6% this year.

Write to Joe Woelfel at

We have $1.5 million we don’t intend to ever use in retirement – how do we invest it if we plan on giving it to our kids one day?

Previous article

Marijuana Stocks To Buy And Watch

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News